This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Ken Blount

Head of External Research at Rebiotix, Inc.

Profile

Ken Blount, PhD, is a seasoned entrepreneur and director of collaborative research in biotech, pharma, clinical, and academia, and his scientific expertise includes microbiome and small-molecule therapeutic development, translational medical oncology, and RNA-targeting therapeutics. Dr. Blount is the Head of External Research at Rebiotix, where he is cultivating a portfolio of novel microbiome therapeutic programs and directing the internal R&D team. Prior to joining Rebiotix, Dr. Blount directed translational oncology research at the Yale Cancer Center and was a cofounder and Director of Biology at BioRelix, a venture-backed company that developed new antibiotics for a novel RNA target class.

Agenda Sessions

Business, Regulatory, and Clinical Strategies to Develop New Microbiome-Directed Therapeutics

Business, Regulatory, and Clinical Strategies to Develop New Microbiome-Directed Therapeutics

Ken Blount -
Head of External Research,
Rebiotix, Inc.

more

Research and business around the microbiome continues to rapidly expand. There are currently many institutions and companies looking at various ways to utilize bugs as drugs. More science and quality parameters are being developed to create, manufacture and commercialize these new and unique medicines to treat various diseases of the microbiome Microbiota Restoration Therapy (MRT) is one example of a new and novel way to provide bugs as drugs utilizing Science and Quality.